Close it

Would you like to become a TBEC member? Please fill out the form below.

By becoming a TBEC member, you agree to endorse the values and the principles of the TB Europe Coalition, and agree with its membership rights and responsibilities.

Membership is free of charge.

TBEC membership rights

TBEC membership responsibilities












Drug-Resistant TB
Civil Society Capacity Building for DR-TB Regional Meeting

Civil Society Capacity Building for DR-TB Regional Meeting

When new, effective medicines providing safe treatment for widespread debilitating diseases, it is vitally important to ensure that everyone who needs such medicines has access to them. It was with this aim therefore that TBEC held a regional meeting on civil society capacity building for DR-TB. Existing TB treatments are incredibly gruelling for the patient, but medical innovations (shorter or safer treatments, new medicines, or more exact methods of diagnosis) can genuinely relieve a patient’s suffering. But what use are such innovations if patients aren’t able to access them? What use are new medicines if there’s no way for hospitals to buy them or any way to prescribe that they are needed? Any measurement of the success of innovative treatments has to be countered by an assessment of their accessibility. When everyone has access to new treatments, we can start to talk about how successful they are. Guidelines on DR-TB Treatment The recent WHO recommendations on drug-resistant TB (DR-TB) are the first in a long time that provide a genuine possibility to start to improve the treatment of DR-TB by using innovative and more effective medicines with less debilitating side effects. It is therefore vital that we do not waste time; More…

Belarus: Key country in the fight against Multi-Drug Resistant TB

Belarus: Key country in the fight against Multi-Drug Resistant TB

In mid May, Daniel Kashnitsky and I joined with Tsira Chakaia and a Tajikistan member of parliament (MP), Jamshed Murtazaqulov, in a joint TBEC and Global TB Caucus (GTBC) visit to Belarus. Our intentions were to explore possible initiatives in Belarus under TB REP2 and also whether there is interest in creating a local MP caucus on TB. Over 3 days we had a fascinating series of meetings with parliamentarians, national health bodies, civil society, the WHO country office, and the British Embassy. The overall picture is very encouraging. Ten years ago, Belarus had some of the worst MDR rates in the world together with poor treatment success rates. Today a combination of improvements in the national programme and the introduction of new drugs, especially Bedaquiline (BDQ), have had a very positive impact. From this year onwards, BDQ is being made available in all parts of the country although there is still work to be done to ensure access to it for all. New case incidence is down from 58 in 2009 to 32 per 100 000 in 2017. Treatment success is up to an impressive 83%. Mortality is going down by around 10% per annum. New cases have dropped More…

First Results of Tuberculosis Programme in Tajikistan

First Results of Tuberculosis Programme in Tajikistan

Within the framework of the Project “Assistance in reducing the burden of tuberculosis in the Republic of Tajikistan” – implemented in the country since May 2018 – 1,499 people have been tested for TB, of which 77 were diagnosed with TB. All 77 have started treatment and have been included in the Social Support Programme. The interim results of one of the project’s components – the Small Grants program – will be summarized in this article by Arthur Niyazov, Project Manager and representative of the international organisation “Project HOPE” in Tajikistan. The Project “Assistance in reducing the burden of tuberculosis in the Republic of Tajikistan” aimed to improve access to diagnostic services, treatment adherence, and patient support for vulnerable groups (specifically, migrants and their families). The international organisation “Project HOPE”, as a sub-recipient of the Global Fund grant, is responsible for the implementation of two important components of the project: the Small Grants programme and the motivational support programme for Drug-Resistant TB patients. The Principal recipient of the grant is the Project Implementation Unit of the Republican Center of Protection of the Population from Tuberculosis. The Small Grants programme aims to improve access to quality services for the diagnosis and More…

Giving MDR-TB Patients a New Lease on Life

Giving MDR-TB Patients a New Lease on Life

Multidrug-resistant tuberculosis (MDR-TB) can be successfully treated today; however, the treatment course can take as long as two years and side effects can be severe if not appropriately addressed. The rate of MDR-TB treatment success is largely dependent on a patient’s socioeconomic circumstances as patients from marginalized groups are particularly vulnerable to dropping out of treatment. That is why ensuring patients’ adherence to TB treatment through a patient-centered approach that engages communities and civil society organizations, is critical to the success of MDR-TB treatment outcomes. Consistent with the principles of the WHO End TB Strategy, Project Hope’s interventions in Tajikistan (within the framework of the Global Fund to fight AIDS, Tuberculosis and Malaria TB grant) have provided a robust foundation for building a strong coalition in which communities and civil society organizations play a crucial role in combatting TB. Trained members of civil society and non-governmental organizations (NGO) have a unique capacity through patient education and psychosocial support to reach out to their communities to ensure that TB and MDR-TB patients make full recovery. One such patient for whom Project HOPE’s community-based initiatives were life-changing is Alisher Latipov. A family man from the Spitamen district in Tajikistan’s Sughd region, Alisher More…

‘The Disease Does not Discourage Me, It Makes Me Stronger’, Says a 28 Years Old Romanian Woman Living with TB

‘The Disease Does not Discourage Me, It Makes Me Stronger’, Says a 28 Years Old Romanian Woman Living with TB

An article recently published in the newsletter of the Romanian Pulmonology Institute “Marius Nasta”, edited in partnership with the Romanian Angel Appeal Fund, tells the story of a young woman diagnosed with MDR-TB. The patient, taken to the Municipal Hospital because of food poisoning, had a chest X-ray among other tests, and discovered that she had multidrug-resistant tuberculosis. Contrary to her worst expectations, she found out that it would take more than three months in hospital and between six to eight months at home to treat the disease. She used to live in a village in Teleorman County, but had to work long hours at a real estate agency in Bucharest, occasionally even skipping meals. That is how her immune system weakened, as she assumes, and she caught TB. However, she decided not to be let down by her disease, but rather to gather all her strength for the sake of her father and sister, who together with our heroine went through the experience of losing their mother just five years before. “The disease does not discourage me, it makes me stronger”, she says, as she talks about the determination to change her life style, as well as the necessity More…

International course on clinical management of M(X)DR-TB for WHO Europe Region countries

International course on clinical management of M(X)DR-TB for WHO Europe Region countries

The WHO Collaborating Centre for Research and Training in Management of MDR-TB in Latvia announced an opportunity for clinicians and responsible for clinical managemnet of DR-TB to join their course. The main objective of the course is to update knowladge of the participants on the latest global development in M(X)DR-TB, as well as develop skills for M(X)DR-TB case management in their respective countries. The course will be available in Russian and English (according to schedule) and will last for 9 working days. For more details about the course please click here: International Advanced Course in clinical management of DR TB. Your completed application (click here: Application form WHO CC ) please send to the Tuberculosis Foundation of Latvia. E: info@ltbf.lv This blog is the product of an activity that has received funding under an operating grant from the European Union’s Health Programme (2014-2020). The content of this blog represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use More…

Ukraine's TB doctors meet to discuss new MDR-TB treatment schemes

Ukraine’s TB doctors meet to discuss new MDR-TB treatment schemes

Clinical trials of a new scheme for treating patients with drug-sensitive and chemo-resistant tuberculosis: next steps On 1-3 July 2015, the working meetings took place with phthsiologists (TB doctors) from Kyiv, Kyiv Oblast and Chernigiv Oblast where new steps were discussed in Ukraine’s participation in clinical trials of a new scheme for treating patients with drug-resistant and chemoresistant TB. TBEC earlier reported that Ukraine has started clinical trials of Pretomanid. The clinical trials were initiated by an international organisation – the Global Alliance for TB Drug Development (TB Alliance). In Ukraine, clinical trials are being conducted by F.G. Yanovsky National Phthisiology and Pulmonology Institute of the National Academy of Medical Sciences of Ukraine with informational support provided by “Ukrainians Against TB” Public Movement” Foundation. As part of the project’s implementation, working meetings had been arranged in Kyiv, Kyiv Oblast and Chernigiv Oblast. The meetings were held: On 1 July – with Kyiv phthisiologists – at F.G. Yanovsky National Phthisiology and Pulmonology Institute of the National Academy of Medical Sciences of Ukraine; On 2 July – with Kyiv Oblast phthisiologists – at Kyiv Oblast Tuberculosis Hospital; On 3 July – with Chernigiv Oblast phthisiologists – at Chernigiv Oblast Tuberculosis Hospital. Overall, more More…

New online tools can speed up TB detection and treatment

New online tools can speed up TB detection and treatment

New results of innovative scientific research a welcome news to TB patients worldwide. Finding out what drugs can be used to treat a patient with TB can now be sped up by days or weeks, thanks to a new free online tool. The tool, called TB-Profiler, was developed by a team of scientists led by Dr Taane Clark at the London School of Hygiene & Tropical Medicine, and is able to analyse and interpret genome sequence data to predict resistance to 11 drugs used for the treatment of TB. Speeding up the process to find appropriate drugs when treating a patient with drug-resistant TB improves the likelihood of cure. By enabling the optimum course of treatment to be selected without delay, toxic drugs found to be ineffective because of resistance can be disregarded, relieving TB patients of damaging, unpleasant, and often long-lasting side effects. Researchers say the TB-Profiler tool – available here, will aid control of drug resistant TB, the emergence of which currently threatens to derail global efforts to control the disease. This rapid tool only takes a few minutes and means that sequence data can now be used without delay. Importantly, it also removes dependence on specialized bioinformatics skills More…

Ukraine has started clinical trials of Pretomanid

Ukraine has started clinical trials of Pretomanid

This was reported on May 28, 2015 during a round table at UKRINFORM agency in Kiev “New treatment regimens for Drug-Resistant TB, based on the newest available drugs” organised by Public Movement “Ukrainians against TB” and the Yanovsky National TB Institute, by head of the TB Institute Department of Chemo-resistant TB Svetlana Cherenko. “Since 2006, Ukraine has shown a decline in TB incidence, but it is very slow. The WHO declared a new strategy for TB control which aims to reduce the number of deaths from the disease by 95% by 2035, but at such a low scale of reducing the incidence in Ukraine, it will at best be able to overcome the disease in 2090. Therefore, it is necessary to accelerate the rates of reducing morbidity and activate all measures against tuberculosis ” – said S. Cherenko. Every year 4000 people die from TB in Ukraine, many of them are patients with MDR-TB. According to WHO, to date the effectiveness of treatment of MDR-TB in the world cohort of patients was 46% in terms of “effective treatment”, said S.Cherenko. In Ukraine, the treatment success rate is only 34%. One reason for the low efficiency of treatment of MDR-TB patients More…

Former Global Fund Chief Warns about a TB crisis in EECA

Former Global Fund Chief Warns about a TB crisis in EECA

The West cannot ignore a growing TB crisis in EECA, says Michel D. Kazatchkine, the former Global Fund Executive Director, and now a UN Secretary General‘s Special Envoy on HIV/AIDS in Eastern Europe and Central Asia, in his recent Huffington Post blog Recalling his recent trip to Uzbekistan, where he was on a mission devoted to HIV/AIDS, TB and MDR-TB, Michel Kazatchkine talks about a surprise to him “to hear medical students in Tashkent, Uzbekistan’s capital city, claiming in a unanimous voice that they see “phtisiology” as the most exciting professional future they wish to consider at the end of their studies” (the term used in Russian is ‘phtisiathry’ – ftiziatria – from Greek фθίσις — ‘spitting blood’ and ἰᾱτρεία — to cure, treat – a branch of clinical care that deals with Tuberculosis, common in all countries of the former USSR). Speaking on his visit to the Republican Scientific and Practical Centre of Phtisiatry and Pulmonology in Tashkent – which is also the reference point for TB in Uzbekistan – (the official web-site of the Centre is available in Russian), M.Kazatchkine commends the Head of the Centre, Professor Tillyashaikhov Nigmatovich, on the 800-beds in-patient facility, on ambulatory sections, a More…

TB Europe Coalition involved in developing new TB Action Plan for Europe 2016-2020

TB Europe Coalition involved in developing new TB Action Plan for Europe 2016-2020

On 3rd October 2014, the TB Europe Coalition was invited by WHO Europe to represent civil society working on tuberculosis across the European region at the first meeting of the Advisory Committee for the development of the “Tuberculosis Action Plan for the WHO European Region, 2016-2020”.   “The Consolidated Action Plan to Prevent and Combat Multidrug and Extensively Drug-Resistant Tuberculosis in the WHO European Region, 2011-2015” commonly known as MAP, was endorsed by the 61st Session of the WHO Regional Committee for Europe in Baku, Azerbaijan, on 15 September 2011. The Plan considers a number of activities in seven areas of intervention to be undertaken by Member States, with assistance of the WHO Regional Office and Partners. After four years of implementation, significant progresses can be reported in the prevention and control of multidrug resistant (MDR) and extensively drug resistant (XDR) tuberculosis (TB) in the Region, but challenges exists particularly in achieving treatment success.   Coming closer to its last year of implementation and with endorsement of the Post 2015 Global TB Strategy by the 67th World Health Assembly, it was time to re-think how Member States, WHO and partners should move forward together in preventing and controlling TB and More…

A new study highlights potential for social media to support MDR-TB patients

A new study highlights potential for social media to support MDR-TB patients

A study – “I can also serve as an inspiration” – a role for social media in supporting patients undergoing treatment for multidrug-resistant tuberculosis (MDR-TB)” – was published this week in PLOS ONE by Médecins Sans Frontières (MSF). It highlights the potential for social media to support patients undergoing treatment for multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). The qualitative research examined the experiences of patients and health staff involved in the ‘TB & ME’ collaborative blogging project for patients undergoing treatment for MDR and XDR TB around the world. The current treatment for MDR-TB can take up to 2 years and has a low cure rate, which is partially because of serious side-effects that make adherence to the TB drugs challenging. Therefore, support for adherence to treatment remains a critical element to cure. Participants in the MSF study reported that blogging was seen to help patients to continue with their treatment. The online audience led to bloggers feeling encouraged by their followers, wanting to set a positive example for others and provided a distraction from the long and difficult treatment. No negative outcomes from taking part in the blogging project were mentioned by those involved in the study. More…

wink.pink